Chia-Kuei Mo

Chia-Kuei Mo

Auto-generated profile, based on publicly available information

Chia-Kuei Mo

Washington University in St. Louis 2

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
CMChia-Kuei Mo
Chia-Kuei Mo
JLJingxian Liu
Jingxian Liu
SCSiqi Chen
Siqi Chen
ESErik Storrs
Erik Storrs
ACAndre Luiz N. Targino da Costa
Andre Luiz N. Targino da Costa
LDLi Ding
Li Ding
To study the spatial interactions among cancer and non-cancer cells1, we here examined a cohort of 131 tumour sections from 78 cases across 6 cancer types by Visium spatial transcriptomics (ST). This was combined with 48 matched single-nucleus RNA sequencing samples and 22 matched co-detection by indexing (CODEX) samples. To describe tumour structures and habitats, we defined ‘tumour microregions’ as spatially distinct cancer cell clusters separated by stromal components. They varied in size and density among cancer types, with the largest microregions observed in metastatic samples. We further grouped microregions with shared genetic alterations into ‘spatial subclones’. Thirty five tumour sections exhibited subclonal structures. Spatial subclones with distinct copy number variations and mutations displayed differential oncogenic activities. We identified increased metabolic activity at the centre and increased antigen presentation along the leading edges of microregions. We also observed variable T cell infiltrations within microregions and macrophages predominantly residing at tumour boundaries. We reconstructed 3D tumour structures by co-registering 48 serial ST sections from 16 samples, which provided insights into the spatial organization and heterogeneity of tumours. Additionally, using an unsupervised deep-learning algorithm and integrating ST and CODEX data, we identified both immune hot and cold neighbourhoods and enhanced immune exhaustion markers surrounding the 3D subclones. These findings contribute to the understanding of spatial tumour evolution through interactions with the local microenvironment in 2D and 3D space, providing valuable insights into tumour biology.

27 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
YWYige Wu
Yige Wu
SCSiqi Chen
Siqi Chen
XYXiaolu Yang
Xiaolu Yang
KSKazuhito Sato
Kazuhito Sato
PLPreet Lal
Preet Lal
FCFeng Chen
Feng Chen
Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an avenue for enhancing treatment efficacy and addressing the limitations of current therapies. To identify effective strategies for treating RCC, we selected ten drugs guided by tumor biology to test in six RCC patient-derived xenograft (PDX) models. The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib and mTORC1/2 inhibitor sapanisertib emerged as the most effective drugs, particularly when combined. The combination demonstrated favorable tolerability and inhibited tumor growth or induced tumor regression in all models, including two from patients who experienced treatment failure with FDA-approved TKI and immunotherapy combinations. In cabozantinib-treated samples, imaging analysis revealed a significant reduction in vascular density, and single-nucleus RNA sequencing (snRNA-seq) analysis indicated a decreased proportion of endothelial cells in the tumors. SnRNA-seq data further identified a tumor subpopulation enriched with cell-cycle activity that exhibited heightened sensitivity to the cabozantinib and sapanisertib combination. Conversely, activation of the epithelial–mesenchymal transition pathway, detected at the protein level, was associated with drug resistance in residual tumors following combination treatment. The combination effectively restrained ERK phosphorylation and reduced expression of ERK downstream transcription factors and their target genes implicated in cell-cycle control and apoptosis. This study highlights the potential of the cabozantinib plus sapanisertib combination as a promising treatment approach for patients with RCC, particularly those whose tumors progressed on immune checkpoint inhibitors and other TKIs.Significance: The molecular-guided therapeutic strategy of combining cabozantinib and sapanisertib restrains ERK activity to effectively suppress growth of renal cell carcinomas, including those unresponsive to immune checkpoint inhibitors.

17 April 2026 in Cancer Discovery
Verified
Journal Article
Open access
ESErik Storrs
Erik Storrs
CMChia-Kuei Mo
Chia-Kuei Mo
WCWen-Hung Chou
Wen-Hung Chou
GBGaurav Bhatt
Gaurav Bhatt
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
Breast and prostate cancers are both hormone-driven adenocarcinomas that undergo analogous invasion programs. Using lightsheet microscopy on intact tumors, we identified transitional junctions between precancerous and invasive regions. We then developed a multimodal serial-section workflow integrating volumetric reconstruction with spatial transcriptomics. Analysis of 319 spatial assays from 51 cases revealed gene-expression features and novel structural insights defining the shift from precancer to invasive disease. In breast cancer, loss of MGP and PLAT was associated with invasive transition and promoted tumorigenesis in functional assays. In prostate cancer, GDF15, ALDH1A3, ANPEP, and FASN were upregulated along invasive progression, and their knockdown in PC-3 cells suppressed proliferation and migration. Enrichment of tumor-associated macrophages (SPP1⁺, MS4A6A⁺) along non-TNBC breast cancer transitions highlights immune involvement as a potential driver of invasiveness.

1 September 2026
Verified
Other
Open access
ESErik Storrs
Erik Storrs
CMChia-Kuei Mo
Chia-Kuei Mo
WCWen-Hung Chou
Wen-Hung Chou
GBGaurav Bhatt
Gaurav Bhatt
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
HT957Z1 HGPIN_GP4 3D rotation.

1 September 2026
Verified
Other
Open access
ESErik Storrs
Erik Storrs
CMChia-Kuei Mo
Chia-Kuei Mo
WCWen-Hung Chou
Wen-Hung Chou
GBGaurav Bhatt
Gaurav Bhatt
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
Supplementary Mov. 6 from Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate

1 September 2026
Verified
Other
Open access
ESErik Storrs
Erik Storrs
CMChia-Kuei Mo
Chia-Kuei Mo
WCWen-Hung Chou
Wen-Hung Chou
GBGaurav Bhatt
Gaurav Bhatt
SCSiqi Chen
Siqi Chen
LDLi Ding
Li Ding
Supplementary Mov. 4 from Spatial Mapping of the Precancer-to-Cancer Transition in Breast and Prostate